Drug Details

General Information of the Drug (ID: DR6890)
Name
L-buthionine sulfoximine
Synonyms
l-buthionine sulfoximine; L-Buthionine-sulfoximine; 83730-53-4; (2S)-2-Amino-4-(butylsulfonimidoyl)butanoic acid; Butanoic acid, 2-amino-4-(S-butylsulfonimidoyl)-, (2S)-; L-Buthionine-(S,R)-sulfoximine; BUTHIONINE SULFOXIME; (2S)-2-Amino-4-(S-butylsulfonimidoyl)butanoic Acid; MFCD00067000; NSC 326231; BRN 2367136; L-Buthionine-(S,R)-sulfoximine, 99%; l-buthionine(s,r)-sulfoximine; L-BSO; Buthionine sulfoximine, L-; L-Buthionine (SR)-sulfoximine; Buthionine-S,R-sulfoximine, L-; L-Buthionine-(S,R)-sulphoximine; NSC-381100; NCIMech_000342; BUTHIONINE-SULFOXIMINE; Lopac0_000221; SCHEMBL62034; CHEMBL261642; D,L-Buthionine-S,R-sulfoximine; CHEBI:94288; DTXSID70894150; HMS3260N03; BSO; Tox21_500221; BDBM50487312; NSC801426; s9728; 1-beta-DL-Buthionine(S,R)sulfoximine; AKOS027320570; CS-W020947; HY-106376A; LP00221; MCULE-5971306528; NSC-326231; NSC-801426; SDCCGSBI-0050209.P002; BSO (L-Buthionine-(S,R)-sulfoximine); NCGC00093690-01; NCGC00093690-02; NCGC00093690-03; NCGC00093690-11; NCGC00260906-01; AS-69850; L-Buthionine-sulfoximine, >=97% (TLC); EU-0100221; B 2515; SR-01000075712; SR-01000075712-1; BRD-A47706533-001-01-8; Q27166100; UNII-EEY8DZS103 component KJQFBVYMGADDTQ-JKYUHCHBSA-N; UNII-LW4108Q0BV component KJQFBVYMGADDTQ-JKYUHCHBSA-N; (R*,S*)-(+-)-2-Amino-4-(S-butylsulfonimidoyl)butanoic acid; (2S)-2-AMINO-4-[BUTYL(IMINO)OXO-??-SULFANYL]BUTANOIC ACID; Butanoic acid, 2-amino-4-((R)-S-butylsulfonimidoyl)-, (2S)-rel-; Butanoic acid, 2-amino-4-(S-butylsulfonimidoyl)-, (R*,S*)-(+-)-; 97590-40-4
    Click to Show/Hide
Molecular Type
Small molecule
Disease Brain cancer [ICD-11: 2A00] Phase 1 [1]
Structure
Click to Download Mol
2D MOL

3D MOL

    Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product
Formula
C8H18N2O3S
PubChem CID
119565
Canonical SMILES
CCCCS(=N)(=O)CCC(C(=O)O)N
InChI
1S/C8H18N2O3S/c1-2-3-5-14(10,13)6-4-7(9)8(11)12/h7,10H,2-6,9H2,1H3,(H,11,12)/t7-,14?/m0/s1
InChIKey
KJQFBVYMGADDTQ-CVSPRKDYSA-N
CAS Number
CAS 83730-53-4
ChEBI ID
CHEBI:94288
Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally
    α. A List of Natural Product(s) Able to Enhance the Efficacy of This Drug
          Arsenic trioxide      Realgar and orpiment     Click to Show/Hide the Molecular Data of This NP
                 Achieving Therapeutic Synergy     Click to Show/Hide
                    Representative Experiment Reporting the Effect of This Combination [2]
                    Detail(s)  Combination Info  click to show the detail info of this combination
                    Molecule(s)
                    Regulation		 Down-regulation Activity GSTK1  Molecule Info 
Pathway MAP
                    In-vitro Model Caki-1 CVCL_0234 Clear cell renal cell carcinoma Homo sapiens
Caki-2 CVCL_0235 Renal cell carcinoma Homo sapiens
NC65 Renal cell carcinoma Homo sapiens
                    Experimental
                    Result(s)		 BSO sensitizes RCC cells to As2O3-induced apoptosis through the down-regulation of the intracellular GSH redox system.
Target and Pathway
Target(s) Tumor necrosis factor receptor type I (TNF-R1)  Molecule Info  [3]
KEGG Pathway MAPK signaling pathway Click to Show/Hide
2 Cytokine-cytokine receptor interaction
3 NF-kappa B signaling pathway
4 Sphingolipid signaling pathway
5 Apoptosis
6 Osteoclast differentiation
7 TNF signaling pathway
8 Adipocytokine signaling pathway
9 Non-alcoholic fatty liver disease (NAFLD)
10 Alzheimer's disease
11 Amyotrophic lateral sclerosis (ALS)
12 Chagas disease (American trypanosomiasis)
13 Toxoplasmosis
14 Tuberculosis
15 Hepatitis C
16 Influenza A
17 HTLV-I infection
18 Herpes simplex infection
NetPath Pathway TGF_beta_Receptor Signaling Pathway Click to Show/Hide
2 TCR Signaling Pathway
Panther Pathway Apoptosis signaling pathway Click to Show/Hide
Pathway Interaction Database Canonical NF-kappaB pathway Click to Show/Hide
2 Signaling events mediated by HDAC Class I
3 TNF receptor signaling pathway
4 Ceramide signaling pathway
5 HIV-1 Nef: Negative effector of Fas and TNF-alpha
6 Caspase Cascade in Apoptosis
Reactome TNFR1-induced proapoptotic signaling Click to Show/Hide
2 Regulation of TNFR1 signaling
3 TNFR1-induced NFkappaB signaling pathway
4 TNFR1-mediated ceramide production
5 TNFs bind their physiological receptors
6 TNF signaling
WikiPathways Inflammatory Response Pathway Click to Show/Hide
2 Apoptosis Modulation by HSP70
3 Cardiac Hypertrophic Response
4 Apoptosis
5 Nanoparticle triggered regulated necrosis
6 Amyotrophic lateral sclerosis (ALS)
7 Integrated Pancreatic Cancer Pathway
8 TNF alpha Signaling Pathway
9 Alzheimers Disease
10 Extrinsic Pathway for Apoptosis
11 Apoptosis Modulation and Signaling
References
Reference 1 ClinicalTrials.gov (NCT00002730) Chemotherapy in Treating Children With Neuroblastoma
Reference 2 Enhancement of arsenic trioxide-induced apoptosis in renal cell carcinoma cells by L-buthionine sulfoximine. Int J Oncol. 2004 Jun;24(6):1489-97.
Reference 3 Tumour necrosis factor and cancer. Nat Rev Cancer. 2009 May;9(5):361-71.
 Download Picture         KEGG Link